{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:26:25Z","timestamp":1753892785930,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671325"],"award-info":[{"award-number":["81671325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Methamphetamine and ketamine are commonly used club drugs. Both of them have been reported to mimic psychotic symptoms of schizophrenia. However, the prevalence and detailed features of psychotic symptoms among methamphetamine use disorder (MUD) and ketamine use disorder (KUD) patients are largely unknown. This study aimed to measure psychotic symptoms among patients with MUD and KUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total sample of 842 patients from voluntary drug rehabilitation centers, including 462 MUD patients and 380 KUD patients, were invited to this study. The Positive and Negative Syndrome Scale (PANSS) was applied to assess psychotic symptoms in these two groups of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of psychotic symptoms was significantly higher among MUD patients than KUD patients (75.1 vs. 50.5%, 95% CI: 3.532 \u2013 11.858, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Compared with KUD patients, MUD patients were more likely to experience positive symptoms (PANSS positive scores: 11.5 \u00b1 6.07 vs. 15.1 \u00b1 8.22, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and negative symptoms (PANSS negative scores: 12.4 \u00b1 6.60 vs. 14.5 \u00b1 8.63, <jats:italic>P<\/jats:italic> &amp;lt; 0.001), but not general symptoms (PANSS general scores: 31.2 \u00b1 13.90 vs. 32.2 \u00b1 15.13, <jats:italic>P<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The current study found that more than half of MUD and KUD patients experienced psychotic symptoms, and that patients with MUD are more likely to experience positive and negative symptoms than patients with KUD. The findings provide a new perspective for exploring the neuropathological mechanism of psychotic symptoms of schizophrenia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2021.786622","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:13:48Z","timestamp":1642482828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Features of Psychotic Symptoms in Methamphetamine Use Disorder Patients and Ketamine Use Disorder Patients: A Cross-Sectional Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Tao","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.watres.2015.07.025","article-title":"Methamphetamine and ketamine use in major Chinese cities, a nationwide reconnaissance through sewage-based epidemiology","volume":"84","author":"Du","year":"2015","journal-title":"Water Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/YCO.0000000000000073","article-title":"The new pattern of drug abuse in China","volume":"27","author":"Sun","year":"2014","journal-title":"Curr Opin Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/00952990.2016.1278449","article-title":"Ketamine and international regulations","volume":"43","author":"Liao","year":"2017","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/10550490490436055","article-title":"Psychiatric symptoms in methamphetamine users","volume":"13","author":"Zweben","year":"2004","journal-title":"Am J Addict."},{"key":"B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/1471-244X-12-221","article-title":"Amphetamine-induced psychosis\u2013a separate diagnostic entity or primary psychosis triggered in the vulnerable?","volume":"12","author":"Bramness","year":"2012","journal-title":"BMC Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40263-014-0209-8","article-title":"Methamphetamine psychosis: epidemiology and management","volume":"28","author":"Glasner-Edwards","year":"2014","journal-title":"CNS Drugs."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.comppsych.2013.01.003","article-title":"The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia","author":"Sulaiman","year":"2014","journal-title":"Compr Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.psychres.2016.01.023","article-title":"Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users","volume":"237","author":"Fan","year":"2016","journal-title":"Psychiatry Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e204693","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11481-011-9288-1","article-title":"Methamphetamine-associated psychosis","volume":"7","author":"Grant","year":"2012","journal-title":"J Neuroimmune Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1124\/pr.114.010397","article-title":"Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease","volume":"67","author":"German","year":"2015","journal-title":"Pharmacol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/npp.2017.291","article-title":"Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway","volume":"43","author":"Hedges","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/mp.2011.171","article-title":"Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology","volume":"17","author":"Stone","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B17","first-page":"56","article-title":"Measurement strategies: the visual analogue scale","volume":"6","author":"Mottola","year":"1993","journal-title":"Decubitus."},{"key":"B18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"B19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fnhum.2014.00537","article-title":"The neurobiology of methamphetamine induced psychosis","volume":"8","author":"Hsieh","year":"2014","journal-title":"Front Hum Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00213-007-1047-x","article-title":"Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study","volume":"197","author":"Stone","year":"2008","journal-title":"Psychopharmacology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J Psychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/schbul\/sbs075","article-title":"Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans","volume":"38","author":"Moghaddam","year":"2012","journal-title":"Schizophr Bull."},{"key":"B24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fncel.2017.00181","article-title":"Glutamate Deregulation in Ketamine-Induced Psychosis-A Potential Role of PSD95, NMDA Receptor and PMCA Interaction","volume":"11","author":"Lisek","year":"2017","journal-title":"Front Cell Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.cub.2017.12.059","article-title":"A perceptual inference mechanism for hallucinations linked to striatal dopamine","volume":"28","author":"Cassidy","year":"2018","journal-title":"Curr Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1073\/pnas.98.1.295","article-title":"Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits","volume":"98","author":"Gao","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","article-title":"The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia","volume":"167","author":"Cohen","year":"2014","journal-title":"Schizophr Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"McCutcheon and J Stone: Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.786622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:13:53Z","timestamp":1642482833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.786622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":29,"alternative-id":["10.3389\/fpsyt.2021.786622"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.786622","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"786622"}}